astrazeneca plc-spons adr (AZN) Key Developments
AstraZeneca to Invest USD 285 Million in New Pharmaceutical Factory in Sweden
May 19 15
AstraZeneca will invest approximately USD 285 million in a new manufacturing facility for its biologics in Sodertalje, Sweden. The facility, which is anticipated to become operational by 2019, is intended for filling and packaging of protein therapeutics, as well as supplying products for AstraZeneca and MedImmune's (the UK firm's biologics research and development unit) clinical studies from the end of 2018. Approximately 150-250 roles are expected to be created at the site by 2019. The expansion of the existing Sodertalje site to include a manufacturing facility for the company's biologics portfolio represents the first phase of a possible three-part programme to increase AstraZeneca's biologics production capabilities.
AstraZeneca Russia and Eurasia Presents at 2015 Russian Pharmaceutical Forum, May-21-2015 10:00 AM
May 16 15
AstraZeneca Russia and Eurasia Presents at 2015 Russian Pharmaceutical Forum, May-21-2015 10:00 AM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Irina Ivanishcheva, Legal Director.
AstraZeneca Russia Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 03:40 PM
May 16 15
AstraZeneca Russia Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 03:40 PM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Yuriy Mochalin, Corporate Affairs Director.
AstraZeneca to Collaborate with Abbott on Developing Companion Diagnostic Tests
May 14 15
AstraZeneca (UK) has entered into a collaboration deal with Abbott for developing companion diagnostic tests in order to identify patients with severe asthma, who are highly likely to benefit from a candidate drug, tralokinumab. According to the agreement, Abbott will be in charge of developing and commercialising diagnostic tests that measure serum levels of the proteins that have been identified as potential predictive biomarkers of up-regulated IL-13 in severe asthma - periostin and dipeptidyl peptidase-4 (DPP4). These diagnostic tests will be developed concurrently with the UK firm's Phase III study assessing tralokinumab for treating patients with severe, inadequately controlled asthma.
AstraZeneca PLC to Update on Progress with Immuno-Oncology Pipeline and Combination Treatments at ASCO 2015
May 13 15
AstraZeneca PLC announced that it will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2015. 61 scientific abstracts2 will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics. Highlights at the ASCO Annual Meeting will include data from across the Company’s broad pipeline of next-generation investigational medicines, which target cancer through key areas of tumor biology including immunotherapy, the genetic drivers of cancer and acquired resistance and DNA damage repair. Immunotherapies use the body's own immune system to help fight cancer. There are three major components to an effective cancer immune response: priming and activation of T-cells (white blood cells that play a central role in immune response) through cancer antigen presentation; optimizing T-cell mediated cancer cell killing by overcoming inhibitory mechanisms employed by the cancer; and overcoming immune suppressive mechanisms in the tumor microenvironment to further enhance an effective anti-tumor immune response. At the ASCO Annual Meeting AstraZeneca will provide an update on its comprehensive immuno-oncology development program, which includes 31 ongoing clinical trials targeted across this cycle of anti-tumor immunity. Data to be presented at ASCO are supported by a number of recent milestones including: Start of the combination arm of the Phase III ARCTIC study of MEDI4736 with tremelimumab in non-small cell lung cancer (NSCLC) patients who have received at least two prior systemic treatment regimens. Start of the Phase II CONDOR study of MEDI4736 and tremelimumab as monotherapies and in combination in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Fast-Track designation granted by the FDA for the investigation of MEDI4736 as a monotherapy treatment for patients with advanced NSCLC, who have received at least two prior systemic-treatment regimens, who do not have EGFR mutations or anaplastic lymphoma kinase (ALK) alterations, and have tumors that are determined to be PD-L1 positive. In addition to testing the potential of immunotherapies in solid tumors, AstraZeneca recently entered into a strategic collaboration  with Celgene, a global leader in haematological cancers, on a broad development program for MEDI4736, both as monotherapy and in combination with other molecules, across a range of blood cancers including multiple myeloma, non-Hodgkin’s lymphoma and myelodysplastic syndrome. Presentations to include: Safety and efficacy of MEDI4736 in combination with tremelimumabin patients with NSCLC. Updated data on additional patients and activity in both PD-L1 positive and negative patients to be presented. Safety and efficacy of the triple combination of MEDI4736 with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in patients with advanced melanoma. An open-label study of MEDI4736 in combination with MEDI0680 (anti-PD-1) in patients with advanced malignancies. Updates reinforcing the clinical activity of MEDI4736 as monotherapy in patients with NSCLC in patients with recurrent or metastatic SCCHN [Abstract #3011], and on the development of a PD-L1 companion diagnostic assay.